Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — SEB Nordic Large Cap Seminar, Stockholm 2020
14 slides from Coloplast A/s Class B's conference presentation, 2020
Slide 1: Making it easier to be yourself
Making it easier to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Stina Leading intimate healthcare SEB Nordic Large Cap Seminar, Stockholm 2020 Anders Lonning-Skovgaard Making life easier Ostomy Care, Con
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2018/19 by segment Group revenue 2018/19 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 36% #1 DKK DKK 17.9bn #1 Other 17.9bn European developed markets markets 59
Slide 4: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 5: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 6: Coloplast has strong market positions in Europe and great commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 13-14bn 12-13bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in %1 Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% reg
Slide 7: Coloplast strengthens Executive Management
Coloplast strengthens Executive Management • Coloplast Executive Leadership Team is expanded from four to six people in order to deliver on upcoming 2025 strategy centred around Innovation and Growth, which will be presented at the Capital Markets Day on September 29th Kristian Villumsen New role EV
Slide 8: An update on how Coloplast is navigating the COVID-19 pandemic
An update on how Coloplast is navigating the COVID-19 pandemic • Three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations • Global guidelines, safety measures and contingency plans implemented • Support consumers with dependable delivery of
Slide 9: Q3 negatively impacted by decline in elective procedures in Interventional Urology and reversal of stock building in EU
Q3 negatively impacted by decline in elective procedures in Interventional Urology and reversal of stock building in EU Q3 Highlights Revenue growth +5% • Negative organic growth of -2% and -4% reported decline in Reported revenue (DKKm) DKK +5% Organic growth 13,321 13,954 • Chronic Care delivered
Slide 10: Financial guidance for FY 2019/20 – guidance range narrowed
Financial guidance for FY 2019/20 – guidance range narrowed Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • The situation in Interventional Urology gradually normalises in Q4 • Majority of 150m stock building from Q2 reversed in Q3 – expected to ~4% fully reverse in Q4 3-4% Sales growth f
Slide 11: Continue to provide attractive cash returns despite large investments in commercial and expansion activities
Continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareholders in
Slide 12: Key highlights from 2018/19 Corporate Responsibility initiatives
Key highlights from 2018/19 Corporate Responsibility initiatives Empowering People Acting respectfully Minimising footprint Our Access to Healthcare programme has New target to increase share of diverse teams Achieved 100% electricity from supported 62 projects since 2007. (gender, generation, natio
Slide 13: Capital Markets Day 2020
Capital Markets Day 2020 14.00 pm - 17.00 pm CEST 13.00 pm - 16.00 pm BST 08.00 am - 11.00 am EDT Join us virtually or at our venue in Humlebaek, north of Copenhagen. This event is intended to give institutional investors and equity analysts an introduction to the new long-term strategy. More inform
Slide 14: Our mission
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /
Coloplast — SEB Nordic Large Cap Seminar, Stockholm 2020 on 6ix